热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　先声药业（02096）盘中涨超7%，截至发稿，股价上涨5.91%，现报10.40港元，成交额1.02亿港元。

　　5月20日，先声药业旗下抗肿瘤创新药公司先声再明宣布，其自主研发的FGFR2b（成纤维细胞生长因子受体2b ）靶点抗体药物偶联物（ADC）候选创新药SIM0686已启动针对晚期实体瘤的Ⅰ期临床研究，并于南京天印山医院完成首例患者给药。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.